Lithium Citrate

CHEMBL2103738 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
210.0 g/mol
LogP
Phase
4

The citrate salt form of lithium used as a mood stabilizer for bipolar disorder, available in liquid formulations. It offers an alternative for patients who have difficulty swallowing lithium carbonate capsules.

Molecular Weight

210.0000 g/mol

TPSA

141.00 Ų

Therapeutic Areas

Mechanism of Action

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O.O.O.O.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Li+].[Li+].[Li+]

InChI

InChI=1S/C6H8O7.3Li.4H2O/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;4*1H2/q;3*+1;;;;/p-3

Molecular Formula

C6H5Li3O7

HBD / HBA

1 / 7

Rotatable Bonds

2

Heavy Atoms

16

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

The citrate salt form of lithium used as a mood stabilizer for bipolar disorder, available in liquid formulations. It offers an alternative for patients who have difficulty swallowing lithium carbonate capsules.

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Yes, Lithium Citrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2103738. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 13520. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.